Literature DB >> 12959299

Stress responses after treatment of hypercholesterolaemia with simvastatin.

A M Nugent1, D Neely, I Young, I McDowell, M O'Kane, N Bell, C F Stanford, D P Nicholls.   

Abstract

In order to determine whether treatment of hyperlipidaemia with simvastatin impairs exercise stress responses and so may contribute to an excess of suicides and violent deaths, the effects of simvastatin 20 mg daily and placebo on exercise physiology were compared in 19 patients. After 6 weeks of treatment there was no evidence of reduced exercise capacity, or of reduced cortisol or catecholamine responses. It is concluded that treatment of hyperlipidaemia with an inhibitor of HMG-CoA reductase does not significantly modify stress responses, and so the explanation for a possible increase in non-cardiac mortality must be sought elsewhere.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 12959299      PMCID: PMC1364624          DOI: 10.1111/j.1365-2125.1993.tb00400.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  Cortisol secretion in patients on simvastatin.

Authors:  R Candrina; G Balestrieri; A Salvi; O Di Stefano; S Spandrio; G Giustina
Journal:  Lancet       Date:  1990-01-06       Impact factor: 79.321

2.  Reproducibility of cardiopulmonary parameters during exercise in patients with chronic cardiac failure. The need for a preliminary test.

Authors:  J S Elborn; C F Stanford; D P Nicholls
Journal:  Eur Heart J       Date:  1990-01       Impact factor: 29.983

Review 3.  Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification.

Authors:  S Yusuf; J Wittes; L Friedman
Journal:  JAMA       Date:  1988-10-21       Impact factor: 56.272

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  Serum cholesterol in aggressive conduct disorder: a preliminary study.

Authors:  M Virkkunen; H Penttinen
Journal:  Biol Psychiatry       Date:  1984-03       Impact factor: 13.382

6.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Authors:  M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

7.  Acute hypothalamic-pituitary-adrenal responses to the stress of treadmill exercise. Physiologic adaptations to physical training.

Authors:  A Luger; P A Deuster; S B Kyle; W T Gallucci; L C Montgomery; P W Gold; D L Loriaux; G P Chrousos
Journal:  N Engl J Med       Date:  1987-05-21       Impact factor: 91.245

8.  Serum cholesterol, triglycerides, and aggression in the general population.

Authors:  F G Fowkes; G C Leng; P T Donnan; I J Deary; R A Riemersma; E Housley
Journal:  Lancet       Date:  1992-10-24       Impact factor: 79.321

9.  Lovastatin treatment inhibits sterol synthesis and induces HMG-CoA reductase activity in mononuclear leukocytes of normal subjects.

Authors:  B G Stone; C D Evans; W F Prigge; W C Duane; R L Gebhard
Journal:  J Lipid Res       Date:  1989-12       Impact factor: 5.922

10.  Serum cholesterol and risk of accidental or violent death in a 25-year follow-up. The Finnish cohorts of the Seven Countries Study.

Authors:  J Pekkanen; A Nissinen; S Punsar; M J Karvonen
Journal:  Arch Intern Med       Date:  1989-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.